Introduction {#Sec1}
============

The increase in obesity levels, because of unhealthy lifestyle, is predicted to significantly augment the incidence of type 2 diabetes. Type 2 diabetes mellitus (T2DM), a metabolic disorder known by high blood glucose, is among the top ten causes of death globally. The global prevalence of diabetes in adults of 20--79 years is now 7.3% (4.8--11.9%) that is estimated to reach to 8.3% (5.6%--13.9%) by 2045 \[[@CR1]\]. There is strong and consistent evidence that obesity management can be beneficial in the treatment of type 2 diabetes \[[@CR2], [@CR3]\]. In overweight and obese patients with type 2 diabetes, modest weight loss has been shown to improve glycemic control and to reduce the need for glucose-lowering medications \[[@CR4]\]. Small studies have demonstrated that in obese patients with type 2 diabetes dietary energy restriction can reduce A1C and fasting glucose in the absence of pharmacologic therapy or ongoing procedures \[[@CR5]\].

Common current medications approved for the treatment of T2DM has a number of limitations, such as side effects and secondary failure; so, much effort has been focused on natural products as complementary or alternative diabetic treatments without side effects or toxicity \[[@CR6], [@CR7]\]. In recent years, it has been reported that probiotics, especially lactic acid bacteria, have efficacy relating to the management of diabetes \[[@CR8]\]. Probiotics, the live microorganisms, present health benefits to the host, especially when administered in sufficient amounts \[[@CR9]\].

The intestinal microbiota could affect the host by influencing bile acid metabolism, body weight, pro-inflammatory status and insulin resistance, and modulating the gut hormones. Modulating gut microbiota by consumption of probiotics could have beneficial effects on glucose metabolism through several mechanisms \[[@CR10]\]. One of the key therapeutic goal in both the prevention and management of T2DM is weight reduction \[[@CR11]\]. Physiologic functions of probiotics would contribute to the health of gut microbiota and can affect appetite and food intake, body weight and composition and metabolic functions through gastrointestinal pathways and modulate the gut bacterial community \[[@CR12]\].

Considering the potential of probiotic bacteria the aim of the present randomized clinical trial was to investigate the effects of *Lactobacillus casei* 01 (*L. casei* 01) supplementation on dietary intake, body weight, and glycemic control in patients with T2DM.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

An 8 week, parallel-group, randomized controlled trial was conducted in the Sheykholrayis Polyclinic of Tabriz University of Medical Sciences, Tabriz, Iran. The recruitment process of participants began in September 2016, and the intervention was carried out in January 2017.

The target population of the present study was patients with T2DM. Subjects were contacted a day before commencing the supplementation, and the study was thoroughly explained to them. Volunteers were composed of 44 patients with T2DM, 30--50 years of age, and body mass index (BMI) lower than 35 kg/m^2^. All patients had been diagnosed with T2DM for at least 1 year. Exclusion criteria were smoking, the presence of kidney, liver, and/or inflammatory intestinal disease, thyroid disorders, immunodeficiency diseases, required insulin injections, use of nutritional supplements within the previous 3 weeks of testing, use of estrogen or progesterone, pregnancy or breast-feeding, consuming any type of antibiotics, and consuming any other probiotic products within the previous 2 months of testing. Primary endpoints were the promotion of SIRT1, reduction of fetuin-A levels, and control of glycemic response, and secondary endpoint was the management of dietary intake and body weight.

The sample size for the current study was calculated on the basis of FBS results reported by Ostadrahimi et al. \[[@CR13]\] with a confidence level of 95% and a power of 80%, which was found to be 18 patients. Taking into account the probable dropout of patients during the intervention course as well as the patients who may not adhere to the study protocol, 22 patients with T2DM were recruited for each group.

Study design and measurements {#Sec4}
-----------------------------

Of 44 patients who had met the inclusion criteria, 4 were excluded because of their unwillingness to participate in the study. Subjects were randomly assigned to the probiotic (n = 20) or placebo (n = 20) group, using a block randomization procedure with stratified subjects in each block based on sex and age. The allocation of the intervention or placebo group was concealed from the researchers, and the probiotic and placebo capsules had both an identical appearance and labeled information. Therefore, neither the subjects nor the investigators were aware of the treatment assignments in this double-blinded study. Over 8 weeks, both groups consumed probiotic capsules containing 10^8^ cfu *L. casei* 01 (Chr. Hansen, Denmark) or placebo capsules. Considering the buffering capacity of the food on the survival of probiotic microbes during gastrointestinal transit \[[@CR14]\], the patients were asked to take the capsules with or just prior to a meal containing some fats. All patients were asked, throughout the 8-week trial, to maintain their usual dietary habits and lifestyle. The patients were instructed to keep the capsules under refrigeration and to avoid any changes in medication, if possible.

Arrangements were made so that the patients would receive the 8-week supply of their probiotic or placebo capsules at the beginning of the trial and were asked to take a capsule daily. Compliance with the capsule consumption guidelines was monitored by telephone interviews once a week. Information on demographic and anthropometric measurements and fasting blood samples were collected at the beginning and at the end of the trial. Nutrient intakes during 3 days were estimated using a 24-h dietary recall at the beginning, in the middle, and at the end of the study. Three-day averages of macro- and micro-nutrient intakes were analyzed by Nutritionist 4 software (First Databank, Hearst Corp, San Bruno, CA, USA). International Physical Activity Questionnaire (IPAQ) \[[@CR15]\] was completed for participants to assess physical activity level.

Anthropometric measurements were recorded by trained personnel. A blood sample was drawn for each patient after an overnight fasting. All whole blood and serum samples were collected and kept at − 70 °C until the assay. Blood samples were analyzed at the Drug Applied Research Center (Tabriz University of Medical Sciences, Tabriz, Iran).

Fasting blood glucose was measured using the standard enzymatic method with the Pars Azmun kit (Karaj, Iran). Glycated hemoglobin (HbA1c) was measured in the whole blood by cation exchange chromatography with the NycoCard HbA1c kit (Oslo, Norway). Insulin concentration was determined by a chemiluminescent immunoassay using a Liaison analyzer (Diameter, Italy). To measure insulin resistance, insulin resistance index, HOMA-IR (Homeostatic Model Assessment of Insulin Resistance), was used: HOMA1-IR = FPI (mg/dl) × FPG (mg/dl))/22.5. Serum fetuin-A and SIRT1 concentrations were measured by human ELISA kits (Diameter, Italy and Bioassay Technology Laboratory, China).

The present study was conducted in accordance with the guidelines laid down in the Declaration of Helsinki, and all procedures were approved by the Ethics Committee of Tabriz University of Medical Sciences (no. IR.TBZMED.REC.1395.402). A written informed consent was obtained from each patient.

Intervention procedure {#Sec5}
----------------------

Hard yellow gelatin capsules were used as delivery vehicle in the present study. *L. casei* 01 was the active agent of the probiotic capsules, and maltodextrin was used as the excipient. The capsules were prepared using a capsule filling device under aseptic condition. To check the quality of probiotic capsules and ensure that an adequate dose of the probiotic was consumed by the experiment group (at least 10^8^ CFU/day), the bacterial count of the capsules was checked by a food technologist at the baseline, in the middle, and at the end of the trial period, by culturing the contents of three capsules at each. The capsules were cultured with the use of MRS agar (De Man, Rogosa and Sharpe agar) via serial dilution and the pour plate technique. Bacterial enumeration of the capsules showed that the capsules contained a minimum of 10^8^ colony-forming units of *L. casei* 01 during the study period The placebo capsules contained only maltodextrin. Since the bacterial count of the excipient could confound the outcomes of the study, the powder was cultured to ensure it was free of pathogens. Capsule count was performed by the researcher at the end of the study to evaluate compliance.

Statistical analyses {#Sec6}
--------------------

Statistical analysis was performed by SPSS software (ver. 17; SPSS Inc. IL, Chicago, USA). Normality of the numeric variables was checked by Kolmogorov--Smirnov test \[[@CR16]\]. Data were presented using mean (SD), median (min--max) for the numeric normal, and non-normal variables, respectively as well as the percentage of frequency for categorical variables. The between-group comparisons of baseline measures and demographic variables were conducted with independent *t*-test and/or Chi square test where appropriate. For within-group comparisons, paired *t*-tests were used, where before and after intervention measurements were taken. To assess the effect of intervention, the analysis of covariance (ANCOVA) was used to control baseline measurements and confounders. In all analyses, *p* values less than 0.05 were considered statistically as significant.

Results {#Sec7}
=======

As revealed in the study flow diagram (Fig. [1](#Fig1){ref-type="fig"}), 40 patients with T2DM \[probiotic (n = 20) and placebo (n = 20)\] completed the trial. Capsule counts showed good compliance on the part of the participants who completed the study, and no adverse effects were reported.Fig. 1Summary of patient flow diagram

Baseline characteristics of the patients are presented in Table [1](#Tab1){ref-type="table"}; there were no significant differences between the two groups with regard to any of the baseline characteristics (p \> 0.05).Table 1Characteristics of the participants under studyVariableplacebo group (n = 20)Intervention group (n = 20)p. valueAge (year)^a^45.00 (5.37)43.95 (8.14)0.629Diabetes duration (month)^a^3.67 (4.00)4.00 (3.81)0.794Sex^b^ Male7 (35.0)7 (35.0)1.00 Female13 (65.0)13 (65.0)Physical activity^b^ Non-active10 (50.0)5 (25.0)0.247 Light-active8 (40.0)11 (55.0) Active1 (5.0)3 (15.0) Heavy-active1 (5.0)1 (5.0)Diet therapy (year)^b^ Yes9 (45.0)8 (40.0)0.749 No11 (55.0)12 (60.0)Glibenclamide^b^ Not used13 (65.0)12 (60.0)0.744 Using more than 1/day7 (35.0)8 (40.0)Metformin^b^ 1--2 tablet/day9 (45.0)8 (40.0)0.749 3--4 tablet/day11 (55.0)12 (60.0)^a^Data are expressed as mean (SD) and *p* value based on independent *t*-test^b^Frequency (percent) is reported and p-value based on Chi squared test

The analysis of dietary questionnaires, which is presented in Fig. [2](#Fig2){ref-type="fig"}, revealed that the two groups had no significant differences for TEI and the intake of carbohydrate, fat, and protein at baseline \[− 54.32 (− 298.83 to 190.29), 0.656; − 10.15 (− 43.24 to 22.94), 0.387; − 2.02 (− 10.20 to 6.15), 0.619; -2.22 (− 11.41 to 6.96), 0.627; respectively\]. Taking a look to Fig. [2](#Fig2){ref-type="fig"} we can find that the TEI and the intake of carbohydrate, fat, and protein was significantly reduced during the intervention period in the probiotic group compared with placebo group \[− 35.80 (− 55.47 to − 16.13), 0.001; − 8.67 (− 13.82 to − 3.52), 0.002; − 4.29 (− 7.45 to − 1.13), 0.009; − 1.35 (− 1.89 to − 0.81), 0.001; respectively\]. Moreover, he within group changes were significant \[p = 0.003, p \< 0.001, p \< 0.001, p = 0.001; respectively\].Fig. 2The effect of *L. casei* 01 supplementation on dietary intake

The effect of consumption of *L. casei* 01 on anthropometric variables is presented in Fig. [3](#Fig3){ref-type="fig"}. The anthropometric variables including weight, BMI, waist circumference, and WHR were not significantly different at baseline between the two groups \[− 6.30 (− 15.74 to 3.14), 0.185; − 2.43 (− 5.47 to 0.60), 0.113; − 5.40 (− 11.54 to 0.74), 0.083; − 0.01 (− 0.05 to 0.03), 0.647; respectively\]. As shown in Fig. [3](#Fig3){ref-type="fig"} consumption of *L. casei* 01 for 2 months significantly decreased weight, BMI, and waist circumference in diabetic patients compared with placebo group \[− 1.52 (− 2.31 to − 0.76), \< 0.001; − 0.84 (− 1.26 to − 0.41), \< 0.001; − 1.77 (− 3.36 to − 0.18), 0.029; respectively\]. Moreover the within group changes were significant in probiotic group \[− 1.20 (− 1.81 to − 0.58), 0.001; − 0.485 (− 0.73 to − 0.23), 0.001; − 2.15 (3.30 to − 0.99), 0.001; respectively\]. Although between-group change for WHR was not significant \[− 0.01 (− 0.02 to 0.00), 0.052)\] the within-group change was statistically significant \[− 0.020 (− 0.031 to − 0.009), 0.001\].Fig. 3The Effect of *L. casei* 01 supplementation on anthropometric variables and blood pressure

The effect of *L. casei* 01 supplementation on biochemical parameters is shown in Fig. [4](#Fig4){ref-type="fig"}. The serum fetuin-A level was significantly decreased and level of SIRT1 significantly increased after 2-month intervention in probiotic group in comparison with placebo group \[− 17.56 (− 32.54 to − 2.58), 0.023; 0.52 (0.026 to 1.02), 0.040; respectively\]. The within group changes were statistically significant \[− 11.90 (− 20.29 to − 3.51), 0.008; 0.52 (0.17 to 0.87), 0.006; respectively\]. After the 2-month intervention, FBS, serum fasting insulin level, and HOMA.IR index significantly reduced in the intervention group compared with placebo group \[− 28.32 (− 50.23 to − 6.41), 0.013; − 3.12 (− 5.90 to − 0.35), 0.028; − 32.31 (− 55.09 to − 9.54), 0.007; respectively\]. The within-group differences for the mentioned glycemic response parameters were significant \[− 28.35 (− 45.39 to − 11.31), 0.002; − 2.33 (− 4.48 to − 0.18), 0.035; − 29.72 (− 45.62 to − 13.82), 0.001; respectively\]. Evaluation of HbA1c after 2-month supplementation showed no significant reduction in probiotic group in comparison with placebo group \[− 0.45 (− 0.96 to 0.05), 0.077\]; moreover the within group reduction was not significant \[− 0.24 (− 0.60 to 0.12), 0.190\].Fig. 4The Effect of *L. casei* 01 supplementation on biochemical parameters

Discussion {#Sec8}
==========

Management of diabetes without any side effects by natural food is a challenge for medical nutrition therapy of diabetes. To the best of our knowledge, this is the first study evaluating the effect of *L. casei* 01 supplementation on dietary intake and anthropometric parameters in patients with T2DM. *L. casei* 01 supplementation for 8 weeks significantly affected dietary intake and anthropometric indexes, including weight, BMI, and waist circumference. Moreover, the outcomes showed that, compared with placebo, *L. casei* 01 supplementation decreased fetuin-A and increased SIRT1 level and improved glycemic response in patients with T2DM.

Probiotics have physiologic functions that contribute to the health of gut microbiota, can affect food intake and appetite, body weight and composition and metabolic functions through gastrointestinal pathways and modulation of the gut bacterial community \[[@CR10], [@CR12]\]. By modulating the gut microbiota, probiotics can affect the energy balance and/or metabolism of the host. Limited evidence exists on the effect of probiotic consumption on weight management in humans. The findings of present trial were in accordance with the study conducted by Kadooka et al. in which they reported that a supplementation of fermented milk with *Lactobacillus gasseri* SBT2055 for 12 weeks induces significant weight loss and a decrease in BMI, waist and hip circumferences, and body fat mass \[[@CR17]\]. Omar et al. showed that the consumption of yogurt supplemented with *Lactobacillus* leads to a decrease in total body fat mass \[[@CR18]\].

A possible way for manipulating the mammalian eating behavior and body weight by probiotic bacteria is appetite-regulating hormones. Supplementation with VSL\#3, containing Lactobacillus strains, in mice reduced appetite-inducing hormones and neuropeptide Y in the hypothalamus \[[@CR19], [@CR20]\]. Moreover the levels of cholecystokinin, leptin, and other satiety peptides, which regulate food intake and hunger by affecting vagus nerve signaling, were improved \[[@CR21]\]. Moreover; probiotics can modulate energy intake and metabolism by the production of short chain fatty acids (SCFAs) from indigestible polysaccharides \[[@CR12]\]. SCFAs such as acetate, butyrate and propionate, produced by bacterial fermentation function as energy substrates, regulates satiety and food intake \[[@CR22]\]. By activating the G-protein-coupled receptors GPR41 and GPR43 on intestinal epithelial cells, SCFAs stimulate peptide YY (PYY) and glucagon-like peptide (GLP)-1 secretion \[[@CR12]\].

According to the results shown in Fig. [4](#Fig4){ref-type="fig"} the level of fetuin-A and SIRT1 was significantly affected by probiotic consumption. The effect of probiotic supplementation on fetuin-A and/or SIRT1 was not evaluated in previous studies. Fetuin-A, a circulating glycoprotein that is secreted by the liver and adipose tissues, inhibits insulin receptor tyrosine kinase activity in animal studies \[[@CR23]\]. Fetuin-A knockout mice have enhanced glucose sensitivity, resistance to weight gain and lower serum-free fatty acid levels \[[@CR24]\]. In humans, the liver-secreted fetuin-A is associated with atherosclerosis, insulin resistance, T2DM, and metabolic syndrome \[[@CR25]\]. In cross-sectional analyses, Ismail et al. \[[@CR26]\] showed that fetuin-A levels were higher in adults and children with obesity and metabolic syndrome. Sirtuins (SIRTs), ubiquitous deacetylase, are main regulators of energy homeostasis and metabolism \[[@CR27]\]. SIRT1 has a positive impact on obesity, diabetes mellitus, liver steatosis, and other metabolic disorders \[[@CR28]\]. Due to its deacetylation activity, SIRT1 influences many steps of glucose metabolism in liver, pancreas, muscle and adipose tissue and regulates insulin secretion \[[@CR29]\]. It has been demonstrated that lean subjects have higher expression of SIRT1 in the adipose tissue compared to obese.

It has been reported that weight loss and caloric restriction (CR) can affect both fetuin-A and SIRT1 levels \[[@CR25], [@CR26]\]. Haukeland et al. \[[@CR30]\] showed that substantial weight loss in children led to a significant decrease in fetuin-A concentrations. Brix et al. \[[@CR31]\] reported that elevated fetuin-A levels in morbid obesity decreased after bariatric surgery. Choi et al. \[[@CR25]\] found that CR significantly decreases hepatic fetuin-A expression and its circulating levels in overweight rats and humans with T2DM. Mariani et al. \[[@CR32]\] found that the reduction of body fat mass was associated with increased plasma SIRT1; moreover they showed that, in addition to the tissue levels, the circulating SIRT1 could be increased by a negative caloric balance. Calorie restriction (CR) has been reported to increase SIRT1 protein levels and activity in mice, rats, and humans \[[@CR33], [@CR34]\].

Considering the effect of calorie restriction and weight loss on fetuin-A and SIRT1 levels it can be understood that by reducing the appetite and dietary intake and body weight, *L. casei* 01 could affect the plasma level of fetuin-A and SIRT1 in patients with T2DM in present trial.

Improvements in glycemic control by probiotic bacteria, as seen in this study, were in accordance with other similar studies conducted previously \[[@CR35]--[@CR38]\]. The antidiabetic property of *Bifidobacteria and Lactobacillus* has been evaluated in human and animal studies \[[@CR8], [@CR36], [@CR39]--[@CR41]\]. Ejtahed et al. \[[@CR42]\] declared that probiotic yogurt, containing *Lactobacillus acidophilus* La5 and *Bifidobacterium lactis* Bb12, decreased fasting blood glucose and HbA1c in patients with T2DM. Ostadrahimi et al. \[[@CR13]\] revealed that consumption of probiotic fermented milk, containing *L. acidophilus*, *L. casei*, and *Bifidobacteria* decreased fasting blood glucose and HbA1c compared with control group. The results of a meta-analysis, conducted by Yao et al. \[[@CR43]\], demonstrated that probiotics supplementation was associated with significant improvement in fasting insulin level in patients with T2DM. Andreasen et al. showed that the intake of *L. acidophilus* NCFM for 4 weeks preserved insulin sensitivity compared with placebo \[[@CR36]\]. Similarly Kobyliak et al. found that supplementation with alive multi-probiotic for 8 weeks was associated with significant reduction of HOMA-IR \[[@CR44]\]. Several possible mechanisms of hypoglycemic effect of probiotics are discussed. Probiotics can affect gut bacteria to produce insulin-tropic polypeptides and GLP-1 (glucagon-like peptide-l) and glucose-dependent insulinotropic polypeptide \[GIP\]; so, increase glucose uptake by muscle, stimulates the liver absorption of blood glucose, and increase in the amount of insulin released from the β cells of the islets \[[@CR43]\]. By modulation of intestinal microbiota composition probiotics can improve intestinal barrier function and diminish the translocation of micro-organisms and their derivatives \[[@CR44]\], from the gut to the systemic circulation, thereby reducing the concomitant release of pro-inflammatory cytokines. Moreover, antioxidant properties of lactic acid bacteria have been shown in previous studies \[[@CR24]\]. Modulating inflammation and oxidative stress has been announced as the possible mechanisms of probiotics' action in improvement of glycemic response in previous researches.

Considering the results of present trial *L. casei* 01 could control glycemic response by controlling dietary intake and body weight and then manipulating the level of fetuin-A and SIRT1 in patients with T2DM. Affecting fetuin-A and SIRT1 levels could be introduce as a new-known mechanism of lactic acid bacteria's action in diabetes management. Further studies on the effects of other probiotic strains on dietary intake, anthropometric indexes, and serum fetuin-A and SIRT1 levels in diabetic patients would be useful.

Evaluating the appetite hormones is suggested to be done in future researches which was the limitation of present trial.

Conclusion {#Sec9}
==========

According to the results of present trial, probiotics affected patients' weight, BMI, and waist circumference by influencing dietary intake. The beneficial effects of probiotics on body weight could be translated into favorable metabolic effects, i.e. improvements in fetuin-A and SIRT1 levels, insulin resistance/glycemic control, and exert beneficial effects on glucose homeostasis. Taking into account the metabolic impacts of SIRT1 and fetuin-A, management of their levels could be effective in diabetes control. The results of present trial helped us to reveal a new mechanism of probiotics action in diabetes and its related metabolic disorders' control.
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